Vertex Pharmaceuticals and CRISPR Therapeutics have amended their collaboration agreement to develop, manufacture and commercialize CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). CTX001 represents the first potential treatment to emerge from the joint research program initiated in […]

Adagio Therapeutics has completed a $336 million Series C financing that will support continued advancement of ADG20, Adagio’s lead clinical candidate being developed as a single agent for both the treatment and prevention of COVID-19, as well as potential future coronaviruses. ADG20 is a monoclonal antibody distinguished from other antibody treatments targeting the COVID-19 by […]

Precision cancer medicine company Tango Therapeutics has entered into a definitive merger agreement with SPAC (special purpose acquisition company) BCTG Acquisition Corp. In addition to the approximately $167 million contributed by BCTG, a group of healthcare investors has committed to participate in the transaction through a common stock PIPE (or private investment in public equity) […]

The Broad Institute of MIT and Harvard have launched the Eric and Wendy Schmidt Center, an initiative funded by a $150 million endowment gift from the Schmidts that will catalyze a new scientific discipline at the intersection of biology and machine learning. Based in Cambridge at the Broad Institute, the center will bring together a global […]

Cambridge biotech Repertoire Immune Medicines has completed a $189 million Series B financing. The company is focused on decoding the immune synapse to create novel immune therapies for cancer, immune disorders, infectious disease, and other serious diseases. Proceeds from this financing will support further expansion of the company’s proprietary DECODE discovery platform, accelerate its clinical […]

Sage Therapeutics and Biogen have reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET). The study achieved its primary endpoint of a statistically significant reduction from baseline compared to placebo. “We are encouraged by the positive results of the KINETIC Study, which indicate that […]

Johnson & Johnson has announced that it is assuming full responsibility regarding the manufacturing of drug substance for its COVID-19 vaccine at contract manufacturer Emergent BioSolutions Maryland facility. Specifically, J&J is adding dedicated leaders for operations and quality, and significantly increasing the number of manufacturing, quality and technical operations personnel to work with the company’s […]

Aveo Oncology has announced FDA approval for Fotivda (tivozanib) for the treatment of adults with renal cell carcinoma (RCC) who meet certain treatment guidelines. Fotivda is a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and was approved in August 2017 in the European Union and other EUSA countries. According to the American Cancer Society, renal cell […]

ElevateBio has raised $525 million in a Series C financing. According to its website, the company has created a business model addressing the most pressing challenges in the field of cell and gene therapy. Its suite of technologies includes gene editing, induced pluripotent stem cells, and protein, viral, and cellular engineering. With this financing, ElevateBio […]

On March 31, following reports in the New York Times and other media sources regarding coronavirus vaccine quality issues at its manufacturing partner Emergent BioSolutions, J & J released an official statement, excerpted below: Since January of 2020, Johnson & Johnson has been working directly with governments, health authorities and other companies to help end […]